Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Immunogenicity of pING-hHER3FL in Patients With Resected Malignancies

NCT03832855 is registered in ClinicalTrials.gov with Herbert Lyerly as lead sponsor.

NCT NCT03832855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03832855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Immunogenicity of pING-hHER3FL in Patients With Resected Malignancies
Lead sponsor
Herbert Lyerly
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 13, 2020
Completion date
March 30, 2030
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer